Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles

Shuyu Xie
Luyan Zhu
Zhao Dong
Yan Wang
Xiaofang Wang
WenZhong Zhou

Department of Preventive Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, People’s Republic of China

Abstract: The purpose of this study was to use solid lipid nanoparticles (SLN) to improve the pharmacological activity of ofloxacin. Ofloxacin-loaded SLN were prepared using palmitic acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier by a hot homogenization and ultrasonication method. The physicochemical characteristics of SLN were investigated by optical microscope, scanning electron microscopy, and photon correlation spectroscopy. Pharmacokinetics was studied after oral administration in mice. In vitro antibacterial activity and in vivo antibacterial efficacy of the SLN were investigated using minimal inhibitory concentrations (MIC) and a mouse protection model. The results demonstrated that the encapsulation efficiency, loading capacity, diameter, polydispersivity index, and zeta potential of the nanoparticles were 41.36% ± 1.50%, 4.40% ± 0.16%, 156.33 ± 7.51 nm, 0.26 ± 0.04, and −22.70 ± 1.40 mv, respectively. The SLN showed sustained release and enhanced antibacterial activity in vitro. Pharmacokinetic results demonstrated that SLN increased the bioavailability of ofloxacin by 2.27-fold, and extended the mean residence time of the drug from 10.50 to 43.44 hours. Single oral administrations of ofloxacin-loaded nanoparticles at 3 drug doses, 5 mg/kg, 10 mg/kg, and 20 mg/kg, all produced higher survival rates of lethal infected mice compared with native ofloxacin. These results indicate that SLN might be a promising delivery system to enhance the pharmacological activity of ofloxacin.

Keywords: ofloxacin, pharmacological activity, solid lipid nanoparticles, antibacterial activity

Introduction

Ofloxacin is one of the most widely available fluoroquinolone antibiotics. It has potent bactericidal activity against a broad range of clinically relevant Gram-negative and Gram-positive pathogens, as well as Mycoplasma, Chlamydia, and Legionella.1–4 This antibiotic has been effectively used to treat a variety of bacterial infections, including those of the respiratory tract, skin structure, bone, gastrointestinal tract, and urinary tract, and bacterial prostatitis, sexually transmitted diseases, and wound and surgical infections.1,3 Ofloxacin is normally administered orally.3

However, the poor aqueous solubility of ofloxacin gives rise to difficulties in the design of pharmaceutical formulations and leads to variable bioavailability.5,6 In addition, almost all of the oral ofloxacin formulations are available only as conventional, immediate-release tablets that require twice daily administration for consecutive days or weeks.7–9 The repeated oral doses of ofloxacin over long time could result in nervous system and gastrointestinal system disorders.10,11 Efforts have been made to develop alternative formulations of ofloxacin to improve therapeutic efficacy and reduce frequency of administration.12–16 Ofloxacin-loaded liposomes
produced higher intracellular drug concentrations and antimicrobial activities. The gastroretentive tablet and sustained-release pellet have been developed for once-daily administration.

Solid lipid nanoparticles (SLN) have attracted increasing attention in pharmaceutics as an alternative dosage form to liposomes and polymeric nanoparticles. SLN possess good tolerability and stability, scaling-up feasibility, and the ability to incorporate hydrophobic/hydrophilic drugs. The incorporation of poorly soluble drugs into SLN can enhance gastrointestinal solubilization, absorption, and bioavailability of drug. Pandey et al demonstrated that 5 oral doses of antitubercular drug-loaded SLN administered every 10 days provided an equivalent therapeutic benefit to 46 daily doses of oral free drugs. Our research showed that SLN could significantly extend systemic circulation times, enhance antibacterial activity in vitro, increase the bioavailability, reduce the dose and frequency of administration, and decrease side effects of tilmicosin.

Fatty acid-SLN reduced the dose and frequency of administration, and antibacterial activity in vitro, increase the bioavailability, significantly extend systemic circulation times, enhance of oral free drugs. Our research showed that SLN could provided an equivalent therapeutic benefit to 46 daily doses of antitubercular drug-loaded SLN administered every 10 days.

In this study, ofloxacin-loaded palmitic acid SLN was prepared using palmitic acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier by a hot homogenization and ultrasonication method. The palmitic acid has been adopted to prepare SLN. PVA is the most commonly used emulsifier in the formulation of nanoparticles due to its excellent mechanical strength, biocompatibility and nontoxicity, and has been approved by the US Food and Drug Administration for medical and food applications. The hot homogenization and ultrasonication method was feasible to prepare poor water solubility drug-loaded SLN. The physicochemical properties and pharmacokinetics of the SLN were investigated and the antibacterial activities of ofloxacin-loaded SLN against Staphylococcus aureus were evaluated in vitro and in vivo.

Materials and methods

Materials

Palmitic acid was bought from Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. (Shanghai, China). Ofloxacin was obtained from Wuhan Konglong Century Technology Development Co., Ltd. (Wuhan, China). PVA was purchased from Sigma-Aldrich (St. Louis, MO, USA). Ofloxacin reference standard was available from China Institute of Veterinary Drug Control (Beijing, China). Methyl alcohol used for high performance liquid chromatography (HPLC) was of liquid chromatography (LC) grade and was purchased from Tedia Company, Inc (USA). The water for HPLC was prepared with a Milli-Q system (Millipore, Bedford, MA). Citric acid was obtained from Sinopharm Chemical Reagent Co., Ltd. (Beijing, China). Other chemicals and reagents not specified in the text were of analytical grade or equivalent.

Animals and bacteria

Kunming species mice (male, 30 ± 1 g) were obtained from the Medical Animal Test Center of Peking University, China. The animals were housed at room temperature under natural day and night cycles with free access to water and normal mice food (Beijing Keao Xieli Co., Ltd., China). They were kept for at least 1 week before use. After experiments, all the surviving mice were sacrificed by cervical dislocation. All experimental protocols concerning the handling of mice were in accordance with the requirements of the Institutional Animal Care and Use Committee at China Agricultural University.

S. aureus (CCVCC2248) was available from China Institute of Veterinary Drug Control (Beijing, China). Bacteria were streaked from glycerol-frozen stocks onto agar plates and incubated overnight at 37°C. A single bacterial colony from the fresh plates was inoculated in the Mueller–Hinton broth (MH) and grown at 37°C in a shaking incubator at 230 rpm to an OD600 of 0.6, which corresponds to ∼8 × 10^6 colony forming units (cfu)/mL, confirmed by plating serial dilutions. For in vitro study, the bacteria were diluted in broth. For in vivo study, the bacteria were collected by centrifugation at 4000 rpm (Centrifuge 5810 R; Eppendorf, Germany) for 10 minutes at 4°C and resuspended in sterile saline at different concentrations.

Preparation of ofloxacin-loaded SLN

Nanoparticles were prepared by a hot homogenization and ultrasonication method. Palmitic acid (4.5 g) and ofloxacin (0.5 g) were added in a 100 mL beaker and heated to 150°C by a homeothermia magnetic stirrer (Shanghai Zhenrong Scientific Instrument Co., Ltd., China). After the drug was dissolved in the melted palmitic acid, the oil phase was poured into 120 mL of boiling 1% PVA solution under magnetic stirring at 150 rpm for 3 minutes to form an oil in water emulsion, and then further sonicated for 5 minutes (VC × 750 Vibra-CellTM, Sonics and Materials, Inc., Newtown, CT, USA, using the 13 mm microprobe with amplitude 35%) to form a nanoemulsion. The hot nanoemulsion was quickly poured into 400 mL cold water to obtain a nanoparticle suspension. The nanoparticles were collected by centrifugation at 12000 rpm (Centrifuge 5810 R;
Eppendorf, Germany) for 60 minutes at 4°C, and washed 3 times with distilled water. The SLN were re-suspended in 120 mL distilled water and lyophilized for 48 hours (LGJ-12 Freeze Dryer; Beijing Songyuanhuaxing Science Technology Development Co., Ltd., China). The control SLN was prepared similarly without adding ofloxacin.

**Microscopic analysis**
Briefly, 5 mg freeze-dried SLN was suspended in 1 mL double distilled water and two micro liters of the suspension were placed on a microscope slide surface. Photomicrographs of the SLN were taken using an inverted optical microscope (Olympus 1X71, Olympus, Japan).

**Scanning electron microscopy (SEM) of nanoparticles**
The morphology of nanoparticles was investigated by SEM (SE S-3400N; HITACHI, Japan). Briefly, 10 mg freeze-dried SLN was suspended in 1 mL distilled water and 2 µL of the suspension was placed on a glass surface. After oven-drying, the samples were coated with gold using an Ion Sputter and examined at an accelerating voltage of 20 kV.

**Determination of loading capacity and encapsulation efficiency**
To determine SLN incorporation capacity, 10 mg freeze-dried SLN was dissolved in chloroform and the solution was analyzed directly at 287.8 nm using a UV spectrophotometer (U-1800, Hitachi Tech Co., Ltd., Japan). The control SLN prepared without drug were treated similarly and used as control for the measurements. The assay was repeated three times using different samples from independent preparations. Loading capacity (LC) and encapsulation efficiency (EE) are defined as follows:27

$$\text{LC} = \frac{(\text{weight of ofloxacin in SLN})}{(\text{weight of SLN})} \times 100\%$$

$$\text{EE} = \frac{(\text{weight of ofloxacin in SLN})}{(\text{weight of ofloxacin added})} \times 100\%$$

**Determination of particle size, polydispersity index, and zeta potential**
The size, polydispersity index (PDI), and zeta potential of ofloxacin-loaded SLN were measured by photon correlation spectroscopy (PCS) using Zetasizer Nano ZS90 (Malvern Instruments, UK) at 25°C. The samples were suspended in distilled water by ultrasonication for 5 seconds at 0°C to remove air bubbles and break up agglomerates. The concentration of sample was 2.7 mg/mL for particle size and PDI, 0.3 mg/mL for zeta potential determinations to get optimum kilo counts per second (kcps) of 20 to 400 for measurements.

**Determination of residual PVA**
The amount of PVA associated with ofloxacin-loaded SLN was determined by a colorimetric method described previously.27 Briefly, 8 mg lyophilized SLN was treated with 2 mL 0.5 M NaOH for 15 minutes at 60°C. Each sample was neutralized with 900 µL 1 M HCl and the volume was adjusted to 5 mL with distilled water. The solution was filtered with 0.22 µm filters and mixed with 3 mL 0.65 M boric acid solution, 0.5 mL I₂/KI (0.05 M/0.15 M) solution and 1.5 mL distilled water. Following incubation at room temperature for 15 minutes, the absorbance was measured at 690 nm using a UV spectrophotometer (U-1800, Hitachi, Japan). A standard plot of PVA was done under identical conditions.

**In vitro release studies**
Ofloxacin-loaded SLN (10 mg) or native ofloxacin (400 µg) were suspended or dissolved in 2 mL 0.1 M sterile hydrochloric acid (donor solution) in a dialysis bag and dialyzed against 45 mL 0.1 M sterile hydrochloric acid (receiver solution) in a 50 mL tube at 37°C under magnetic stirring at 100 rpm. To determine the ofloxacin amount diffused through the dialysis bag, samples (2 mL) were taken from the receiver solution and the same amount of fresh 0.1 M sterile hydrochloric acid was added to keep a constant volume at fixed time points. The sink conditions were maintained for release study. Ofloxacin in the samples was measured spectrophotometrically at 287.8 nm using a UV spectrophotometer (U-1800, Hitachi Tech Co., Ltd., Japan). The control nanoparticles without ofloxacin were treated similarly and used as blanks for the measurements.

**Antibacterial activity studies**
Minimal inhibitory concentrations (MIC) were determined by the Clinical and Laboratory Standards Institute (CLSI) micro-dilution method.28 S. aureus (100 µL, concentration ∼1 × 10⁶ cfu/mL) was added to each well of a 96-well plate containing 100 µL of ofloxacin-loaded SLN suspension in MH. The final bacterium concentration in individual wells was ∼5 × 10⁵ cfu/mL. The final ofloxacin concentrations were 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 µg/mL. The plate was incubated at 37°C and the MIC was determined as the lowest concentration with clear wells at 12, 24, 36, and 48 hours. The MIC of native and released ofloxacin was measured in the same way.
Pharmacokinetics study
Before initiation of the experiment, 50 mice were randomly divided into 10 groups with 5 animals in each group. Then 0.3 mg naked ofloxacin dissolved in 200 µL sterile distilled water or 6.8 mg ofloxacin-SLN containing 0.3 mg ofloxacin suspended in 200 µL sterile distilled water was administered orally to each mouse. At different time points (0.08, 0.17, 0.33, 0.5, 1, 2, 4, 8, 12, 18, 24, 36, 48, 72, 96, 120 hours) post-administration, blood samples were taken from the tail vein and the drug levels in the plasma were assayed. For each treatment, 5 groups of mice were contained and the blood samples (500 µL) were collected in turn from 5 groups over the observation period because of the limited blood volume that could be safely collected from each mouse.

HPLC assay
Ofloxacin concentrations in plasma were determined by HPLC. The method consists of reverse-phase chromatography and fluorimetric detection. Chromatographic conditions were as follows: excitation wavelength, 360; emission wavelength, 465; column, VP-ODS 250 mm × 4.6 mm (Shimadzu Cooperation, Kyoto, Japan); mobile phase, 0.05 mol/L citric acid (pH of the aqueous phase was adjusted by triethylamine to 3.5)/acetonitrile (85/15, v/v); flow rate, 1 mL/min; column temperature, 25°C. Sample extracts were prepared by mixing 100 µL plasma with 200 µL mixture of methyl alcohol and acetonitrile (1/1 v/v). The mixtures were vortexed for 3 minutes to allow complete mixing, followed by centrifugation at 14000 rpm (Sigma 1-14; Sartorius, Germany) for 25 minutes. Then 50 µL supernatant was used for HPLC analysis. The plasma concentration of ofloxacin was found to be linear over the range 0.06 to 4 µg/mL. The correlation coefficient was 0.9996. The lowest value of the standard curve (0.056 µg/mL) was taken as the limit of quantitation. The recovery for the plasma ofloxacin from 3 concentrations (0.1, 1, and 4 µg/mL) was 80.13% ± 5.14%, 87.37% ± 3.51%, and 89.25% ± 2.19%, respectively. The relative standard deviations (RSD) of accuracy and precision for 3 different plasma concentrations of ofloxacin (0.1, 1, and 4 µg/mL) were 5.38%, 2.99%, and 1.86% for intra-day analysis, and 4.58%, 3.03%, and 1.40% for inter-day analysis, respectively.

Pharmacokinetic analysis
The data of plasma ofloxacin concentration-time were analyzed based on noncompartmental pharmacokinetics using the PK Solutions 2.0 (Ashland, OH, USA) computer software.

In vivo efficacy studies
Determination of the minimum lethal dose: bacteria (0.3 mL at concentrations of 3 × 10⁹, 6 × 10⁹, and 12 × 10⁹ cfu/mL) were injected intraperitoneally into each mouse of 3 groups with 10 mice in each group. Mice deaths were observed every 12 hours over a 72-hour period to determine the inoculum size of lethal infection.

Drug treatment and efficacy evaluation: 70 mice were randomly divided into 7 groups with 10 animals in each group. Each mouse was injected intraperitoneally with the minimum lethal infection inoculum size of bacteria. Infected mice were orally administrated with a single dose of ofloxacin-loaded SLN (suspended in 200 µL sterile distilled water) or native ofloxacin (dissolved in 200 µL sterile distilled water) 2 hours post-infection. The dose of ofloxacin was 5 mg/kg, 10 mg/kg, and 20 mg/kg, respectively. A separate group of control animals was administrated orally with 200 µL sterile water. Animals were observed every 12 hours and deaths were recorded over a 120-hour period.

Statistical methods
The data on loading capacity, encapsulation efficiency, particle size, and PDI, as well as zeta potential and pharmacokinetic parameters were analyzed using one-way ANOVA. Significance was evaluated at a P value of 0.05. Statistical analysis was performed using Microsoft Excel (2003).

Results
Physicochemical characteristics of SLN
Photographs showed that SLN were spherical (Figure 1B), well dispersed with good particle size distributions (Figure 1A). Further PCS analysis demonstrated that the
mean particle size of SLN was 156.33 ± 7.51 nm with PDI 0.26 ± 0.04 and zeta potential −22.70 ± 1.40 mV. The loading capacity and encapsulation efficiency of SLN were 4.40% ± 0.16% and 41.36% ± 1.50%. The residual PVA associated with the SLN was 1.28% ± 0.12% (Table 1).

In vitro release
In vitro release curve of ofloxacin-SLN exhibited a biphasic pattern (Figure 2). There was a fast phase with about 34.33% drug released within the initial 24 hours, followed by a slow and sustained phase. The amount of cumulated drug over 120 hours was 49.15%. In the ofloxacin solution control, the release was about 92.45% within 2 hours and reached 100% by 24 hours.

In vitro antibacterial activity
In vitro antibacterial activity studies showed that the MIC of the native ofloxacin increased with the increase of incubation time. The released ofloxacin had the same MIC as the native ofloxacin at all time points. At 12 hours ofloxacin-SLN had the same MIC as native ofloxacin, but later ofloxacin-SLN had a lower MIC than native ofloxacin (Table 2).

Pharmacokinetics
After oral administration of ofloxacin solution, plasma drug concentration reached a peak level of 1.2 μg/mL at 0.60 hours, then slowly decreased (Figure 3). The plasma drug level dropped to 0.08 μg/mL by 12 hours and was undetectable by 18 hours. In the SLN groups, ofloxacin reached a significantly higher peak concentration of 3.64 μg/mL at 0.33 hours, then decreased sharply to the same levels of native drug 1 hour post-administration. Although the plasma drug concentration similarly decreased to 0.09 μg/mL at 12 hours, the concentration was maintained over 0.08 μg/mL for up to 48 hours in the nanoparticles groups.

The AUC₀–∞ value of ofloxacin-loaded SLN was 2.27-fold higher than those obtained with the ofloxacin solution (Table 3). The elimination half-life (T₁/₂el) and the mean residence time (MRT) were also enhanced significantly compared with the ofloxacin solution.

In vivo antibacterial efficacy
The mortality rates of mice infected with the 3 inoculations (3 × 10⁹, 6 × 10⁹, and 12 × 10⁹ cfu) were 60%, 100%, and 100%, respectively (Figure 4). The inoculation of 6 × 10⁹ cfu/mL was selected as the minimum lethal inoculation size and used for the subsequent treatment studies.

Figure 5 shows the survival rates of infected mice treated with ofloxacin-loaded SLN and ofloxacin solution. The survival curves show that SLN is superior to ofloxacin solution. The proportion of survivors for 5 mg/kg, 10 mg/kg, and 20 mg/kg doses in ofloxacin-loaded SLN groups were 3/10 (30%), 5/10 (50%), and 6/10 (60%) over the observed period, respectively, compared with 0/10 (0%), 3/10 (30%), and 3/10 (30%) in ofloxacin solution groups.

Discussion
In this study, ofloxacin-loaded SLN were prepared by a hot homogenization and ultrasonication method. In this method, the choice of lipid is crucial in the formulation design. Lipids must be selected based on their ability to solubilize the drug.

| Table 1 | Physicochemical characteristics of ofloxacin-loaded solid lipid nanoparticles (mean ± SD, n = 3) |
|-------------------------------|-------------------------------|
| EE (%) | LC (%) | MD (nm) | PDI | ZP (mv) | RP (%) |
| 41.36 ± 1.50 | 4.40 ± 0.16 | 156.33 ± 7.51 | 0.26 ± 0.04 | −22.70 ± 1.40 | 1.28 ± 0.12 |

**Abbreviations:** EE, encapsulation efficiency; LC, loading capacity; MD, mean diameter; PDI, polydispersity index; ZP, zeta potential; RP, residual PVA.

| Table 2 | Minimal inhibitory concentrations (MIC) of ofloxacin (n = 3) |
|-------------------------------|-------------------------------|
| Ofloxacin | MIC (µg/mL) |
| | 12 h | 24 h | 36 h | 48 h |
| Native | 0.2 | 0.4 | 0.5 | 0.5 |
| Released | 0.2 | 0.4 | 0.5 | 0.5 |
| SLN-loaded | 0.2 | 0.3 | 0.3 | 0.3 |

**Abbreviation:** SLN, solid lipid nanoparticles.
Palmitic acid was selected because of its high dissolution of ofloxacin, although other lipids such as hydrogenated castor oil had better characteristics used as lipid matrices to prepare SLN.\textsuperscript{23,27} Hydrogenated castor oil-SLN was an effective nanoparticle system for controlled release and enhancement of pharmacological activities of encapsulated drugs,\textsuperscript{23,27} but ofloxacin hardly dissolved in the melted lipid. Ofloxacin had good retention in the drug–lipid mixture once it was dissolved. The drug did not crystallize from the melted palmitic acid even when the temperature of the mixture decreased from 150°C to 85°C. Therefore, the ofloxacin could stay dispersed in the melted lipid during the emulsification process, and the status was maintained during the fast cooling of the emulsion. Part of the drug diffused into the PVA solution, resulting in lower drug encapsulation efficiency and loading capacity.\textsuperscript{19} In addition, the drug maintained its stability and antibacterial activity because the temperature in the preparation did not exceed the melting point of ofloxacin (270 to 275°C). The preparation resulted in consistent nanoparticles of 156.33 ± 7.51 nm with narrow size distribution. The small size of nanoparticles is favorable for improving the per oral performance of incorporated poorly soluble drugs.\textsuperscript{30}

The initial fast release of the drug could be due to desorption and diffusion of ofloxacin accumulated at the oil–water interface and in the outer shell of nanoparticles.\textsuperscript{17,19,23,24} The initial release should be sufficiently rapid to ensure that the therapeutic drug levels are achieved in a timely manner in vivo. The subsequent slow release is mainly due to the slow diffusion of drug molecules through the lipid matrix of the nanoparticles.\textsuperscript{17–19} Slow drug release will contribute to maintaining the effective therapeutic drug concentrations.

In vitro antibacterial activity studies showed that the MIC of native ofloxacin increased with the increase of incubation time. This could be explained by the fact that the native drug gradually loses its effect and bacteria that escaped drug action can multiply rapidly.\textsuperscript{31} SLN enhanced the antibacterial efficacy of ofloxacin against \textit{S. aureus} evaluated by MIC, possibly because of better penetration of nanoparticles into the bacterial cells and better delivery of drug to its site of action.\textsuperscript{30,32} Sustained release of nanoparticles could also enhance the antibacterial efficacy of antibiotics.\textsuperscript{24,31}

SLN significantly increased the bioavailability and extended the systemic circulation of ofloxacin. This could be attributed to a number of reasons. Because of their large surface area, SLN could improve the dissolution rate and level of drug in the presence of gastrointestinal fluids,\textsuperscript{29,30} leading to shorter $T_{\text{max}}$ and higher peak plasma ofloxacin concentration. In addition, SLN may adhere to the gastrointestinal tract wall or enter the intervillar spaces because of their small particle size, thus increasing their residence time in the gastrointestinal tract.\textsuperscript{33,34} Moreover, nanoparticles could protect the drug from chemical and enzymatic degradation and gradually release drug from the

**Table 3** Pharmacokinetic parameters of ofloxacin after oral administration in mice (mean ± SD, \(n = 5\))

| Formulation | MRT (h) | AUC\(_{\text{0→∞}}\) (mg/h/L) | $C_{\text{max}}$ (μg/mL) | $T_{\text{max}}$ (h) | $T_{1/2\text{abs}}$ (h) | $T_{1/2\text{el}}$ (h) |
|-------------|---------|----------------------------|--------------------------|---------------------|-----------------------|---------------------|
| SLN         | 43.44 ± 13.36\textsuperscript{a} | 12.24 ± 1.50\textsuperscript{a} | 3.64 ± 0.48\textsuperscript{a} | 0.33\textsuperscript{a} | 0.06 ± 0.03\textsuperscript{a} | 28.72 ± 9.66\textsuperscript{a} |
| Solution    | 10.50 ± 2.81   | 5.39 ± 0.45   | 1.12 ± 0.12   | 0.60 ± 0.22   | 0.17 ± 0.05   | 9.10 ± 1.63   |

*Notes:* \(^a\)Statistical significance compared with solution, \(P < 0.05\).

*Abbreviations:* MRT, mean residence time; AUC\(_{\text{0→∞}}\), area under the concentration–time curve from zero to infinity; $C_{\text{max}}$, maximal ofloxacin concentration in plasma; $T_{\text{max}}$, time to reach $C_{\text{max}}$; $T_{1/2\text{abs}}$, absorption half-life; $T_{1/2\text{el}}$, elimination half-life.
lipid matrix into blood, resulting in a several-fold increase in MRT compared with native drug.

Although the sustained-release performance of the ofloxacin-loaded SLN was not as good as that of the other drug-loaded SLN in our previous studies, the concentration of 0.09 µg/mL was therapeutically effective for many common pathogens.

The determination of survivorship in an experimental mouse infection model remains a primary model for evaluation of efficacy of antimicrobial agents. The higher proportions of survivors indicate that SLN enhanced the in vivo antimicrobial efficacy of ofloxacin. Previous research suggests that the therapeutic activities of fluoroquinolones in experimental infections are related to their pharmacokinetic behavior. Ofloxacin exhibits concentration-dependent antibacterial activity. The higher AUC and peak plasma concentrations (C_max) can improve its bactericidal efficacy. The sustained release could result in better in vivo efficacy. Although the sustained plasma concentration was lower than the MIC of ofloxacin against S. aureus, ofloxacin penetrates efficiently throughout the body, with concentrations in tissues and body fluids reported to be higher than those in plasma. Besides, the long post-antibiotic effect of ofloxacin can prevent bacteria regrowth even when plasma and tissue concentrations decrease below MIC. The interaction of SLN with bacteria might also enhance the in vivo bactericidal efficiency of ofloxacin, but further experiments need to be done to elucidate this effect.
Conclusion

Oxofloxin was successfully incorporated into palmitic acid-SLN by a hot homogenization and ultrasonication method. SLN had a sustained-release effect and enhanced antibacterial activity against S. aureus in vitro. SLN significantly improved the bioavailability, systematic circulation time, and in vivo efficacy of oxofloxin. The nanoparticle system would be an effective vehicle for oral delivery of oxofloxin to improve its pharmacological activity.

Acknowledgments

This work was supported by the Innovation Fund for Graduate Student of China Agricultural University (kycx2010051).

Disclosure

The authors declare no conflicts of interest.

References

1. Todd PA, Faulds D. Oxofloxin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs. 1991;42:825–876.
2. Saito A, Sawatari K, Fukuda Y, et al. Susceptibility of Legionella pneumonia to oxofloxin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985;28:15–20.
3. Monk JP, Campoli-Richards DM. Oxofloxin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987;33:346–391.
4. Grüneberg RN, Felmingham D, O’Hare MD, et al. The comparative in-vitro activity of oxofloxin. J Antimicrob Chemother. 1988;22 Suppl C:9–19.
5. Martinez M, McDermott P, Walker R. Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals. Vet J. 2006;172:10–28.
6. Okonogi S, Oguchi T, Yonenochi E, Puttipipatkhachorn S, Yamamoto K. Improved dissolution of oxofloxin via solid dispersion. Int J Pharm. 1997;156:175–180.
7. Agro AS, Garner ET, Wright JW, de Escobar C, Villeda B, Seidlin M. Clinical trial of ototopical oxofloxin for treatment of chronic suppurative otitis media. Clin Ther. 1998;20:744–759.
8. Gentry LO, Rodriguez-Gomez G. Oxofloxin versus parenteral therapy for chronic oseomyelitis. Antimicrob Agents Chemother. 1991;35:538–541.
9. Wang F, Gu XJ, Zhang MF, Tai TY. Treatment of typhoid fever with oxofloxin. J Antimicrob Chemother. 1989;23:785–788.
10. Marrier JF, Ducharme MP, DiMarco M, et al. Two open-label, randomized, crossover studies assessing the bioequivalence of oxofloxin administered as immediateand extended-release formulations in healthy subjects. Clin Ther. 2008;28:2070–2080.
11. Yew WW, Kwan SY, Ma WK, Khin MA, Chan PY. In-vitro activity of oxofloxin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother. 1990;26:227–236.
12. Chavanapati M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for oxofloxin: In vitro and in vivo evaluation. Int J Pharm. 2005;304:178–184.
13. Cui Y, Zhang Y, Tang X. In vitro and in vivo evaluation of oxofloxin sustained release pellets. Int J Pharm. 2008;360:47–52.
14. Chavanapati MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for oxofloxin. Int J Pharm. 2006;316:86–92.
15. Furneri PM, Fresta M, Puglisi G, Tempera G. Oxofloxin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000;44:2458–2464.
16. Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of oxofloxin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release. 2008;129:100–106.
17. Xie SY, Wang SL, Zhao BK, Han C, Wang M, Zhou WZ. Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2008;67:199–204.
18. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliver Rev. 2001;47:165–196.
19. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
20. Zhang ZW, Bu HH, Gao ZW, Huang Y, Gao F, Li YP. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394:147–153.
21. Müller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317:82–89.
22. Pandey R, Sharma S, Kuller GK. Oral solid lipid nanoparticle-based antibacterial chemotherapy. Tuberculosis. 2005;85:415–420.
23. Han C, Qi CM, Zhao BK, et al. Hydrogensenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther. 2009;32:116–123.
24. Wang XF, Zhang SL, Zhu LY, et al. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. Vet J. 2011. In press.
25. Xie SY, Zhu LY, Dong Z, et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces. 2011; doi:10.1016/j.colsurfb.2010.12.014.
26. DeMerlis CC, Schoneker DR. Review of the oral toxicity of polypvinyl alcohol (PVA). Food Chem Toxicol. 2003;41:319–326.
27. Xie SY, Pan BL, Wang M. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine. 2010;5:693–701.
28. Clinical and Laboratory Standards Institute. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters: Approved Standard. 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA; 2001.
29. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid – An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73:1–15.
30. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release. 2006;114:53–59.
31. Misra R, Acharya S, Dilnawaz F, Sahoo SK. Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(e-caprolactone) nanoparticles. Nanomedicine. 2009;5:519–530.
32. Esmaeili F, Hosseini-Nasra M, Rad-Malekshahia M, Samadi N, Atyabi F, Dinarvand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine. 2007;3:161–167.
33. Duchêne D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? J Control Release. 2000;44:2458–2464.
34. Vasir JK, Tamberkar G, Karg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003;255:13–32.
35. Hoogkamp-Korstanje JAA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparflaxin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother. 1997;40:427–431.
36. Zal O, O’Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother. 1991;35:1527–1531.
37. Craig WA. Pharmacokinetic-pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12.
38. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (L-oxefloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992;36:860–866.
39. Lode H, Borner K, Koepe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998;27:33–39.
40. Wise R, Lockley MR. The pharmacokinetics of ofloxacin and a review of its tissue penetration. J Antimicrob Chemother. 1988;22 Suppl C: 59–64.
41. Howard BMA, Pinney RJ, Smith JT. Post-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes. Chemotherapy. 1993;39:265–271.